Grand News Network | November 8, 2023

Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook

Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating the consensus of $1 billion.

The company reported adjusted EPS of $2.72, beating the Wall Street estimate of $2.37.

Acquisitions contributed 0.2% to consolidated third-quarter revenue growth. The impact of foreign currency translation benefited reported revenue growth by 1.4%. The divestiture of the Avian Vaccine business in December 2022 reduced reported revenue growth by 1.9%. 

Excluding the ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner